The in vitro activity of Bay 09867, a new quinoline derivative, was compared with those of norfloxacin, nalidixic acid, ceftazidime, cefaclor, cefuroxime, gentamicin, and other antimicrobial agents, when appropriate, against 410 A new cluinoline derivative, 1-cyclopropyl-6-fluro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride (Bay 09867) (Fig. 1 Inocula were prepared in the following manner. For all strains except those of B. fragilis, streptococci (including pneumococci), N. gonorrhoeae, and H. influenzae, the organisms were grown overnight in nutrient broth yielding a viable count of about 109 CFU/ml. H. influenzae, B. fragilis, and streptococcal strains were grown overnight in Levintal broth, thioglycolate broth, and Todd-Hewitt broth, respectively, yielding comparable viable counts. Pneumococci were also grown in Todd-Hewitt broth, and the viable count was 108 CFU/ml. N. gonorrhoeae strains were grown overnight on a chocolate agar plate, and the growth was removed just before use and suspended in peptone water to yield a viable count of 106 and 107 CFU/ml. Two inocula of 104 and 106 CFU, respectively, were used to test all the strains except N. gonorrhoeae and the pneumococci and were obtained by transferring 1 ,ul of an appropriate dilution of the overnight culture to the surface of the antibiotic-containing agar by a multipoint inoculating device (Denley-Tech Ltd., Billingshurst, England 
A new cluinoline derivative, 1-cyclopropyl-6-fluro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride (Bay 09867) ( Fig. 1) , is being developed by Bayer Pharmaceuticals for oral and parenteral use. The molecular weight of Bay 09867 is 367.8. Quinoline derivatives such as nalidixic acid (5) and cinoxacin have been widely used for many years, and the more recently studied norfloxacin (MK-0366, AM-715) (3, 4) and DL 8280 (6) , which have structural similarities and are piperazinyl substituted, have structures resembling that of Bay 09867. In this study, the activity of Bay 09867 has been compared with those of other antimicrobial agents against a wide range of recent clinical isolates and also against strains known to be resistant to certain of these agents.
MATERIALS AND METHODS
Strains and antimicrobial agents. Of a total of 445 strains examined in this study, 410 were recent clinical isolates from patients in Dudley Road Hospital, Birmingham, England (see Table 1 ). The remaining were characterized 1-lactamase producers (8) and known gentamicin-and nalidixic acid-resistant strains.
The antimicrobial agents evaluated in this study were An increase in inoculum to 106 CFU resulted in, at most, a twofold reduction in susceptibility to Bay 09867, nalidixic acid, norfiloxacin, gentamicin, ceftazidime, and cefuroxime, but a greater effect was noted with cefaclor.
Bay 09867 was 4-to 8-fold more active than norfloxacin and at least 64-fold more active than nalidixic acid. Five strains of E. coli, four of Klebsiella spp., four of Proteus mirabilis, and seven of indole-positive Proteus spp. were highly resistant to nalidixic acid (MIC, >128 94/ml); these strains tended to be less susceptible to Bay 09867 (i.e., MIC, 0.06 to 0.5 pg/ml) than were nalidixic acid-susceptibile strains (MIC, 58 pg/ ml). Three strains (one each of Klebsiella spp., Acinetobacter sp., and Providencia stuartii) were resistant to ceftazidime (MIC, >8 Pg/ml), and all were susceptible to Bay 09867 (MIC, sO.5 pgIml).
Bay 09867 displayed high activity against Pseudomonas aeruginosa, being about eightfold more active than ceftazidime. Ten strains were gentamicin resistant (MIC, >4 pg/ml), but all were highly susceptible to Bay 09867; for example, one strain with a gentamicin MIC of >128 ,ug/ml was susceptible to 0.06 pg of Bay 09867 per ml. One strain which was less susceptible to norfloxacin (MIC, 16 jg/ml) was the least susceptible to Bay 09867 (MIC, 2 "g/ml).
Bay 09867 was considerably more active than the other agents studied against H. influenzae, and the 3-lactamase-producing strains were as susceptible as the non-3-lactamase producers. One strain considered to possess a permeability barrier to 1-lactams (,-lactamase negative and an ampicillin MIC of 4 pg/ml) was susceptible to 0.008 ,ug of Bay 09867 per ml. The activity of Bay 09867 against S. aureus was four-fold higher than that of norfloxacin. The nine methicillinresistant strains were less susceptible to the 1B-lactams than were the other strains tested but were equally susceptible to norfloxacin and Bay 09867. Seven gentamicin-resistant strains (MIC, >8 pg/ml) were also included, and these were susceptible to Bay 09867 (MIC, O0.25 jIg/ml).
Bay 09867 was somewhat less active than the ,B-lactams ainst Streptococcus pneumoniae but was fourfold more active than norfloxacin; nalidixic acid possessed no activity. Two strains known to be less susceptible to penicillin (MIC, 0.25 and 0.5 "g/ml) were susceptible to 0.5 and 1 jig ofBay 09867 per ml, respectively. The activity of Bay 09867 against Lancefield group D streptococci was comparable to that of benzylpenicillin. Five 
